Summary
Abbott Laboratories (ABT) filed an 8-K on January 26, 2022, to announce its fourth quarter and full-year 2021 financial results. The filing primarily incorporates a press release (Exhibit 99.1) that details these results. Investors should note that Abbott, as is common practice, utilizes non-GAAP financial measures alongside GAAP. These non-GAAP measures are adjusted to exclude items considered unusual or unpredictable, such as acquisition-related expenses, restructuring costs, litigation, and others, with the aim of providing a clearer view of ongoing operational performance. Management uses these measures internally for performance assessment and believes they offer valuable insights to investors. While the specific financial figures are detailed in the furnished press release, the 8-K itself serves as the official notification of their release. Investors are encouraged to review the referenced press release for comprehensive details on revenue, earnings, and other key performance indicators for Q4 and FY2021. The CFO, Robert E. Funck, Jr., signed the report, affirming the company's disclosures.
Key Highlights
- 1Abbott Laboratories announced its Q4 and full-year 2021 financial results via an 8-K filing on January 26, 2022.
- 2The core of the filing is a press release (Exhibit 99.1) containing the detailed financial results.
- 3Abbott uses non-GAAP financial measures, adjusted for specified items, to provide greater visibility into ongoing operational performance.
- 4Adjustments in non-GAAP measures include expenses from acquisitions, restructuring, litigation, and other unusual items.
- 5Management uses these non-GAAP measures internally and believes they offer useful insights to investors.
- 6Investors are advised to consider these non-GAAP measures in conjunction with, not as a substitute for, GAAP financial measures.
- 7The filing was signed by Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer.